AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,181.50GBp
4 Sep 2015
Change (% chg)

-66.00p (-1.55%)
Prev Close
4,247.50p
Open
4,227.00p
Day's High
4,280.00p
Day's Low
4,179.50p
Volume
3,297,143
Avg. Vol
2,478,919
52-wk High
4,931.68p
52-wk Low
3,746.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for... (more)

Overall

Beta: 0.59
Market Cap(Mil.): £52,845.27
Shares Outstanding(Mil.): 1,263.79
Dividend: 57.50
Yield (%): 4.36

Financials

  AZN.L Industry Sector
P/E (TTM): 68.42 35.80 35.95
EPS (TTM): 0.61 -- --
ROI: 2.91 15.54 14.99
ROE: 5.85 16.12 15.87
Search Stocks

AstraZeneca wins U.S. approval for longer use of blood thinner

- U.S. regulators have approved a new dose of AstraZeneca's blood thinner Brilinta for longer-term use in patients with a history of heart attacks, boosting prospects for a drug the company thinks will eventually sell $3.5 billion a year.

04 Sep 2015

UPDATE 2-AstraZeneca wins U.S. approval for longer use of blood thinner

* AstraZeneca targeting Brilinta sales of $3.5 bln by 2023 (Adds executive and analyst comments on Brilinta growth)

04 Sep 2015

FDA approves longer-term use of AstraZeneca blood thinner

- AstraZeneca Plc on Thursday said the U.S. Food and Drug Administration approved a new dose of its blood thinner Brilinta intended for longer-term use in patients with a history of heart attack or a condition known as acute coronary syndrome.

03 Sep 2015

UPDATE 1-FDA approves longer-term use of AstraZeneca blood thinner

Sept 3 - AstraZeneca Plc on Thursday said the U.S. Food and Drug Administration approved a new dose of its blood thinner Brilinta intended for longer-term use in patients with a history of heart attack or a condition known as acute coronary syndrome.

03 Sep 2015

FDA approves expanded indication for AstraZeneca's blood thinner

Sept 3 - AstraZeneca Plc said the U.S. Food and Drug Administration had approved a new dose of its blood thinner, Brilinta, for patients with a history of heart attack beyond the first year.

03 Sep 2015

BRIEF-AstraZeneca enters license agreement with Daiichi Sankyo

* AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of Flumist in Japan

02 Sep 2015

Valeant picks up AstraZeneca psoriasis drug after Amgen exit

- Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.

01 Sep 2015

UPDATE 1-Valeant picks up AstraZeneca psoriasis drug after Amgen exit

Sept 1 - Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.

01 Sep 2015

Valeant gets right to develop AstraZeneca's psoriasis drug

Sept 1 - Canada's Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.

01 Sep 2015

AstraZeneca names Genentech's Bohen as chief medical officer

LONDON - British pharmaceutical company AstraZeneca named Sean Bohen as its chief medical officer, in an appointment that it said could help accelerate the development of new oncology and immunology medicines.

24 Aug 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks